Systemic lupus erythematosus (SLE): Changing concepts and challenges for the new millennium

Australian and New Zealand Journal of Medicine

Volumn 28, Issue 1, 1998, Pages 5-12

  Rasaratnam, I ^a,c   Ryan, P F J ^b  

^a EPWORTH HOSPITAL   (Australia)

^b The Alfred   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; BIOLOGICAL PRODUCT; BROMOCRIPTINE; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HEPARIN; HYDROXYCHLOROQUINE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPID ANTIBODY; PRASTERONE; PREDNISOLONE; TAMOXIFEN; THALIDOMIDE;

ANTIPHOSPHOLIPID SYNDROME; ARTHRALGIA; ARTHRITIS; AUTOIMMUNE DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEVER; HEMATOLOGIC DISEASE; HUMAN; NEPHROTIC SYNDROME; NEUROPSYCHIATRY; PERICARDITIS; PLEURISY; REVIEW; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; TENOSYNOVITIS;

EID: 0031889090     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1998.tb04451.x     Document Type: Review

References (29)

1. Boumpas DT, Fessier BJ, Austin HA et al. Systemic lupus erythematosus: emerging concepts. Part 2: Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality and pathogenesis (review). Ann Intern Med 1995; 123: 42-53.
2. Rasaratnam I, Ryan PFJ. Lupus: advances and remaining challenges. Med J Aust 1995; 163: 398-9.
3. Hochberg MC. The incidence of systemic lupus erythematosus in Baltimore, Maryland, 1970-1977. Arthritis Rheum 1985; 28: 80-6.
4. Hochberg MC. Systemic lupus erythematosus. Rheum Dis Clin North Am 1990; 16: 617-39.
5. Anstey NM, Bastian I, Dunckley H et al. Systemic lupus erythematosus in Australian Aborigines: High prevalence, morbidity and mortality. Aust NZ J Med 1993; 23: 646-51.
6. Samanta A, Feehally J, Roy S et al. High prevalence of systemic disease and mortality in Asian subjects with systemic lupus erythematosus. Ann Rheum Dis 1991; 50: 490-2.
7. Pistiner M, Wallace DJ, Nessim S et al. Lupus erythematosus in 1980s. A survey of 570 patients. Semin Arthritis Rheum 1991; 21: 55-64.
8. Steinberg AD. Systemic lupus erythematosus: theories of pathogenesis and approach to therapy. Clin Immunol Immunopath 1994; 72: 171-6.
9. Tsao BP, Wallace DJ. Genetics of systemic lupus erythematosus. Curr Opin Rheumatol 1997; 9: 377-9.
10. Arnett FC Jr. The genetics of human lupus. In: Wallace DJ, Hahn BH (Eds). Dubois' lupus erythematosus. Baltimore: Williams & Wilkins, 1997: 77-117.
11. Tsao BP, Cantor RM, Kaluman KC et al. Evidence for linkage of a candidate chromosome I region to human systemic lupus erythematosus. J Clin Invest 1997; 99: 725-31.
12. Petri M, Robinson C. Oral contraceptives and systemic lupus erythematosus. Arthritis Rheum 1997; 40: 797-803.
13. Sanchez-Guerro J, Karlson E, Liang MH et al. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Arthritis Rheum 1997; 40: 804-8.
14. Sanchez-Guerro J, Liang MH, Karlson EW et al. Post menopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Intern Med 1995; 122: 430-3.
15. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
16. Reilly PA, Evison G, McHugh NJ et al. Arthropathy of hands and feet in systemic lupus erythematosus. J Rheumatol 1990; 17: 777-84.
17. Panush RS, Edwards NL, Longley S et al. 'Rhupus' syndrome. Arch Intern Med 1988; 148: 1633-6.
18. Canadian Hydroxychloroquine Study Group. A randomised study of the effect of withdrawing hydroxychloroquine sulphate in systemic lupus erythematosus. N Engl J Med 1991; 324: 150-4.
19. Barlow JE, Austin HA III, Tsokos GC et al. NIH Conference: lupus nephritis. Ann Intern Med 1987; 106: 79-94.
20. Boumpas DT, Austin HA, Vaughan EM et al. Severe lupus nephritis: controlled trial of pulse methylprednisolone versus two different regimens of pulse cyclophosphamide. Lancet 1992; 340: 741-4.
21. Gourley MF, Austin HA, Scott D et al. Methylprednisolone and cyclophosphamide, alone or the combination, in patients with lupus nephritis. A randomised, controlled trial. Ann Intern Med 1996; 125: 549-57.
22. Strand V. Approaches to the management of systemic lupus erythematosus. Curr Opin Rheumatol 1997; 9: 410-20.
23. Abu-Shakra M, Urowitz MB, Gladman DD et al. Mortality studies in systemic lupus erythematosus. Results from a single centre. 1. Causes of Death. J Rheumatol 1995; 22: 1259-64.
24. Jonsson H, Nived O, Sturfelt G. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine 1989; 68: 141-50.
25. Petri M, Spence D, Bone LR et al. Coronary artery disease risk factors in the Johns Hopkins Lupus cohort: prevalence, recognition by patients and preventive practices. Medicine 1992; 71: 291-302.
26. Cowchock FS, Reece EA, Balaban D et al. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomised trial comparing prednisolone with low dose heparin treatment. Am J Obstet Gynecol 1992; 166: 1318-23.
27. Rai R, Cohen H, Dave M et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (on antiphospholipid antibodies). BMJ 1997; 314: 253-7.
28. Silver RK, MacGregor SN, Sholl JS et al. Comparative trial of prednisolone plus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am J Obstet Gynecol 1993; 169: 1411-7.
29. Laskin CA, Bombardier C, Hannah ME. Prednisolone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med 1997; 337: 148-53.